HURA (TuHURA Biosciences) Liabilities-to-Assets : 0.59 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. TuHURA Biosciences's Total Liabilities for the quarter that ended in Sep. 2024 was $2.45 Mil. TuHURA Biosciences's Total Assets for the quarter that ended in Sep. 2024 was $4.14 Mil. Therefore, TuHURA Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2024 was 0.59.

TuHURA Biosciences Liabilities-to-Assets Historical Data

The historical data trend for TuHURA Biosciences's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Liabilities-to-Assets Chart

TuHURA Biosciences Annual Data

Trend

Dec21

Dec22

Dec23

Liabilities-to-Assets

1.12

0.19

1.36

TuHURA Biosciences Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Dec23	Mar24	Jun24	Sep24
Liabilities-to-Assets	Get a 7-Day Free Trial			0.31	1.36	2.05	1.49	0.59

Competitive Comparison of TuHURA Biosciences's Liabilities-to-Assets

For the Biotechnology subindustry, TuHURA Biosciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TuHURA Biosciences's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TuHURA Biosciences's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where TuHURA Biosciences's Liabilities-to-Assets falls into.

TuHURA Biosciences Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

TuHURA Biosciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )	=	Total Liabilities	/	Total Assets
	=	5.921	/	4.362
	=	1.36

TuHURA Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2024 is calculated as

Liabilities-to-Assets (Q: Sep. 2024 )	=	Total Liabilities	/	Total Assets
	=	2.445	/	4.14
	=	0.59

TuHURA Biosciences (NAS:HURA) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

TuHURA Biosciences Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

TuHURA Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Liabilities-to-Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612

Website

https://www.tuhurabio.com

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.